PARIS, July 12 /PRNewswire-FirstCall/ -- (EUR millions) 2007 2006 07/06 % sales % sales % change Southern Europe (1) 23.22 72.0 20.53 71.8 13 Other EU countries (2) 7.69 23.8 6.91 24.2 11 Other markets 1.34 4.2 1.17 4.0 15 SLIT 25.11 77.9 21.76 76.1 15 SCIT 5.65 17.5 5.36 18.7 5 Other products 1.49 4.6 1.49 5.2 - Total Q2 sales 32.25 100.0 28.61 100.00 13 Southern Europe (1) 56.53 75.6 48.10 74.9 18 Other EU countries (2) 15.76 21.1 13.71 21.4 15 Other markets 2.51 3.3 2.39 3.7 5 SLIT 59.75 79.9 49.42 77.0 21 SCIT 11.82 15.8 11.63 18.1 2 Other products 3.23 4.3 3.15 4.9 3 Total HY1 sales 74.80 100.0 64.20 100.00 17 (1) Portugal, Spain, France, Italy, Greece (2) Including Switzerland
2007 second quarter sales registered further strong growth in all markets (+13%, vs +11% in 2006).
The most buoyant segment of the market remained desensitisation via the sublingual route (SLIT, +15%), whose reputation was enhanced by the launch of allergen tablets. Germany posted the strongest growth of the segment over the quarter (+28% increase in initial treatments, vs +9% in all markets).
Cumulated sales for the 1st half-year increased by +17% (vs +14% in 2006). This good performance enables the Group to firmly confirm its double-digit growth guidance for 2007.
The marketing authorisation process for ORALAIR(R) Grasses in Germany is ongoing. The registration file is currently under examination by the German agency Paul Ehrlich Institute.
The launch of ORALAIR(R) Grasses in Germany is being actively prepared by Stallergenes' sales force for the end of the year. This launch will progressively be extended to other European countries as the mutual recognition procedure successfully progresses throughout Europe.
About Stallergenes
Stallergenes is a European biopharmaceutical company dedicated to desensitization treatments for the prevention and cure of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma.
Pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 15% of its sales to Research and Development and is today fully involved in the development of a new therapeutic family, the sublingual desensitization tablets.
With headquarters in France, Stallergenes markets its products in approximately 40 countries. Stallergenes realised 2006 sales of EUR 126.5 million, of which half outside France.
Stallergenes' shares are listed on Eurolist Compartment B of the Euronext Paris Stock Exchange.
ISIN code: FR0000065674, Reuters code: GEN.PA, Bloomberg code: GEN.FP
Please visit our website for additional information: www.stallergenes.com
StallergenesCONTACT: Your contacts Stallergenes: Albert Saporta, Chairman, ChristianThiry, Chief Financial Officer, Tel: +33-(0)1-55-59-20-95,investorrelations@stallergenes.fr; Pavie Finance: Lucile de Fraguier,Investor and Analyst Relations, Tel: +33-(0)1-42-15-04-39,contact@pavie-finance.com
